As compared with a high level of BECN1 mRNA expression, a low level of BECN1 mRNA expression was strongly associated with HER2-enriched breast tumors (odds ratio 8.5 [95% CI 4.4 to 17.9], P = 8.5E− 14); with basal-like breast tumors (odds ratio 35.5 [95% CI 16.4 to 91.8], P = 3.8E− 43); with the presence of TP53 mutations (odds ratio 7.1 [95% CI 5.0 to 10.4], P = 2.6E− 32), and with tumor grade III (odds ratio 10.3 [95% CI 5.6 to 19.2], P = 2.4E− 17). This evidence concerns the gene ERBB2 and breast neoplasm.